Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-16-117939
Filing Date
2016-05-05
Accepted
2016-05-05 18:37:51
Documents
2
Period of Report
2016-05-05

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4247
2 POA DOCUMENT poa.txt EX-24.3_652106 3903
  Complete submission text file 0001209191-16-117939.txt   9570
Mailing Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139
Business Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address INTELLIA THERAPEUTICS, INC. 130 BROOKLINE STREET, SUITE 201 CAMBRIDGE MA 02139
Business Address
Rivera Jose E (Reporting) CIK: 0001671870 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37766 | Film No.: 161625441